Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 14/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 13/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11856554 | 0.73 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4227685 | 0.72 | LTA4H (0.40) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL4216825 | 0.69 | OPRL1 (0.40) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL11845382 | 0.69 | OPRL1 (0.38) | OPRL1DRD2DRD1MEN1MAPT | |
| SCHEMBL7809671 | 0.69 | MEN1 (0.63) | DRD2DRD1MEN1MAPTCYP2C9 | |
| SCHEMBL8314136 | 0.68 | PNMT (0.45) | OPRL1SIGMAR1OPRM1OPRK1OPRD1 | |
| SCHEMBL9575839 | 0.66 | MEN1 (0.50) | DRD2DRD1MEN1MAPTCYP2C9 | |
| SCHEMBL9099385 | 0.64 | DRD2 (0.49) | DRD2DRD1MEN1MAPTCYP2C9 | |
| SCHEMBL9193862 | 0.63 | MEN1 (0.52) | DRD2DRD1MEN1MAPTCYP2C9 | |
| SCHEMBL7896659 | 0.62 | DRD2 (0.48) | DRD2DRD1MEN1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767691-B2 | Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system | GLAXO GROUP LIMITED (GB) | 2010-08-03 | — | — | US | disclosed |
| US-20080194618-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194618-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | OPRL1 33/4885DRD2 546/4885DRD1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.